Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles

Drug Metabolism and Disposition

Volumn 27, Issue 6, 1999, Pages 655-666

  Roy, Partha ^a   Yu, Li J ^a   Crespi, Charles L ^b   Waxman, David J ^a  

^a BOSTON UNIVERSITY   (United States)

^b Gentest Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTOCHROME P450; IFOSFAMIDE; PRODRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CATALYST; DRUG ACTIVATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG RESEARCH; ENZYME ANALYSIS; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CELL LINE; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; IFOSFAMIDE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING;

ANIMALIA; INSECTA; UNIDENTIFIED BACULOVIRUS;

EID: 0033051029     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Aoyama T, Nagata K, Yamazoe Y, Kato R, Matsunaga E, Gelboin HV and Gonzalez FJ (1990) Cytochrome b5 potentiation of cytochrome P-450 catalytic activity demonstrated by a vaccinia virus-mediated in situ reconstitution system. Proc Natl Acad Sci USA 87:5425-5429.
2. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV and Gonzalez FJ (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388-10395.
3. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K and Frei EI (1992) Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumor response. J Clin Oncol 10:995-1000.
4. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
5. Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD and Idle JR (1996) Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol 38:147-154.
6. Brain EG, Yu LJ, Gustafsson K, Drewes P and Waxman DJ (1998) Modulation of P450-dependent ifosfamide pharmacokinetics: A better understanding of drug activation in vivo. Br J Cancer 77:1768-1776.
7. Bunting KD and Townsend AJ (1996) Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J Biol Chem 271:11891-11896.
8. m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7:211-221.
9. Chang TK, Yu L, Maurel P and Waxman DJ (1997b) Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 57:1946-1954.
10. Chang TKH, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophy 311:437-442.
11. Chang TKH, Weber GF, Crespi CL and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637.
12. Chen L and Waxman DJ (1995) Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55:581-589.
13. Chen TL, Passos-Coelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM and Grochow LB (1995) Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 55:810-816.
14. Clarke L and Waxman DJ (1989) Oxidative metabolism of cyclophosphamide: Identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 49:2344-2350.
15. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK and Waxman DJ (1997) Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
16. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235.
17. Crespi CL and Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203-210.
18. Crespi CL and Penman BW (1997) Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 43:171-188.
19. Ekins S, Vanden Branden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV and Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259.
20. Faber OK, Mouridsen HT and Skovsted L (1975) The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man. Br J Clin Pharmacol 2:281-285.
21. Fleming RA (1997) An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17:146S-154S.
22. Goldstein JA and de Morais SM (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
23. Gonzalez FJ and Korzekwa KR (1995) Cytochromes P450 expression systems. Annu Rev Pharmacol Toxicol 35:369-390.
24. Hickman D, Wang JP, Wang Y and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
25. Newton DJ, Wang RW and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
26. Phillips IR and Shephard EA ed (1998) Cytochrome P450 protocols. Methods Mol Biol 107: 103-167.
27. Ren S, Yang JS, Kalhorn TF and Slattery JT (1997) Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 57:4229-4235.
28. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF and Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4:39-42.
29. Romkes M, Faletto MB, Blaisdell JA, Raucy JL and Goldstein JA (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily [published erratum appears in Biochemistry 1993 Feb 9;32(5):1390]. Biochemistry 30:3247-3255.
30. Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K and Watlington CO (1992) Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 294:206-214.
31. Schuetz JD, Beach DL and Guzelian PS (1994) Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11-20.
32. Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S and Yamazaki H (1997) Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401-408.
33. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
34. Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37:301-355.
35. Sladek NE (1993) Oxazaphosphorine-specific acquired cellular resistance, in Drug Resistance in Oncology (Teicher BA, ed.) pp 375-411, Marcel Dekker, New York.
36. Tavassoli M, Ozols J, Sugimoto G, Cox KH and Eberhard UM (1976) Localization of cytochrome b5 in rat organs and tissues by immunohistochemistry. Biochem Biophys Res Commun 72:281-287.
37. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH and Idle JR (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47:1157-1163.
38. Waxman DJ, Attisano C, Guengerich FP and Lapenson DP (1988) Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 263:424-436.
39. Waxman DJ, Chen L, Hecht JED and Jounaidi Y (1999) Cytochrome P450-based cancer gene therapy: Recent advances and future prospects. Drug Metab Rev 31:503-522.
40. Waxman DJ and Walsh C (1983) Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: Purification, characterization, and interactions with metyrapone and cytochrome b5. Biochemistry 22:4846-4855.
41. Weber GF and Waxman DJ (1993) Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem Pharmacol 45:1685-1694.
42. Wrighton SA, Ring BJ and VandenBranden M (1995) The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol Pathol 23:199-208.
43. Yamano S, Nhamburo PT, Aoyama T, Meyer UA, Inaba T, Kalow W, Gelboin HV, McBride OW and Gonzalez FJ (1989) cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: Identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28:7340-7348.
44. Yamazaki H, Johnson WW, Ueng YF, Shimada T and Guengerich FP (1996) Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5. J Biol Chem 271:27438-27444.
45. Yang TJ, Krausz KW, Shou M, Yang SK, Buters JT, Gonzalez FJ and Gelboin HV (1998) Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol 55: 1633-1640.
46. Yu LJ, Drewes P, Gustafsson K, Brain EGC, Hecht JED and Waxman DJ (1999) In vivo modulation of alternative pathways of P450-catalyzed cyclophosphamide metabolism: Impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 288:928-937.
47. Yu L and Waxman DJ (1996) Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Dispos 24:1254-1262.
48. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD and Idle JR (1996) Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 41:13-19.